Invitrogen™ IFNAR2 Monoclonal Antibody (MMHAR-2)

Description

This antibody neutralizes human IFN-alpha receptor, interacting with the extracellular domain. It binds to human IFN-alpha receptor with high affinity and blocks biological action of Type I IFNs. To measure bioactivity, interferon was titrated with the use of a cytopathic effect inhibition assay, where one neutralization unit is the amount of antiserum required to neutralize one unit of human interferon alpha to a 50% endpoint. In this antiviral assay, approximately one unit/mL of interferon was necessary to produce a cytopathic effect of 50%. Purity is >95% by SDS-PAGE and endotoxin level <1 EU/ug. Store at -20°C for up to 6 months. For long-term storage, store at -70°C for retention of full activity. Thaw product by incubation in cold water and aliquot into separate vials, adding 0.1% BSA for additional stability. Refreeze product using a dry ice or a dry ice/alcohol bath. Packaged by and distributed for PBL Assay Science.

The type I interferons, IFN-alpha and IFN-beta, are a group of structurally and functionally related proteins that are induced by either viruses or double-stranded RNA and are defined by their ability to confer an antiviral state in cells. IFN-alpha and IFN-beta appear to compete with one another for binding to a common cell surface receptor, while immune IFN (IFN-gamma) binds to a distinct receptor. This distinct receptor, IFN-alphaR, is only weakly responsive to type I interferons, in contrast to IFN-alpha/betaR, which binds to and responds effectively to IFN-beta and to several of the IFN-alpha subtypes. IFN-alpha/betaR is expressed as two alternatively spliced transcripts, designated IFN-alpha/betaRalpha (IFN-alpha/betaR1) and IFN-alpha/betaRbeta (IFN-alpha/betaR2), both of which are involved in signal transduction and ligand binding.